BioPharmaSpec is a US-based contract research organisation (CRO) which specialises in biopharmaceutical analysis. It has just announced plan to open a new facility in Vilnius, Lithuania, early next year.
The Lithuanian branch will conduct discovery research and offer preclinical characterisation services for a range of biopharma products, says a representative of Investuok Lietuvoje (Invest Lithuania), which is the country’s foreign investment promotion agency.
“The investment from BioPharmaSpec will reinforce Lithuania’s position as an attractive destination for sophisticated R&D operations in the biotechnology sector,” explains Invest Lithuania’s general manager, Elijus Civilis.
The founder of BioPharmaSpec, Prof Howard Morris, adds that “the combination of a well-educated talent pool, a reasonable cost base and the country’s growing biotech industry – all of that aligns perfectly with our strategic goals.”
BioPharmaSpec operates in the US, the UK, India and Europe.
Source: BNS
(Reproduction of BNS information in mass media and other websites without written consent of BNS is prohibited.)
